Inotersen, which was already approved for treatment of ATTR-polyneuropathy, showed no significant changes in echocardiographic parameters in the NEURO-TTR trial, a randomized, double-blind, placebo-control phase III trial where 172 patients with ATTR-polyneuropathy with and without cardiomyopathy were examined [69]. The gene discussed is TTR; the disease is polyneuropathy.